ARTICLE | Company News

Ariad, Merck deal

March 3, 2014 8:00 AM UTC

Ariad disclosed in its 4Q13 and 2013 earnings that partner Merck is terminating an amended 2007 deal under which the pharma had exclusive, worldwide rights to develop and commercialize ridaforolimus for cancer indications. The termination will be effective on Nov. 20, at which time rights to ridaforolimus will be returned to Ariad. Merck has paid Ariad $75 million in upfront and milestone payments under the deal and had been responsible for up to $489 million in additional milestones. Ariad declined to disclose plans for the small molecule inhibitor of mammalian target of rapamycin ( mTOR; FRAP; RAFT1). ...